Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, will present on Thursday, September 19, 2024, at 12:45 PM ET in New York.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Fate Therapeutics' website. The archived version will be available shortly after the event concludes. This conference appearance provides an opportunity for Fate Therapeutics to showcase its innovative pipeline and progress in the field of cellular immunotherapies to a global audience of healthcare professionals and investors.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference. L'azienda, che si concentra sullo sviluppo di immunoterapie cellulari derivate da iPSC per il cancro e le malattie autoimmuni, presenterà il suo intervento giovedì 19 settembre 2024, alle 12:45 PM ET a New York.
Investitori e parti interessate possono accedere a una diretta webcast della presentazione tramite la sezione 'Eventi e Presentazioni' del sito web di Fate Therapeutics. La versione archiviata sarà disponibile poco dopo il termine dell'evento. Questa partecipazione alla conferenza offre a Fate Therapeutics l'opportunità di mettere in mostra il suo innovativo pipeline e il progresso nel campo delle immunoterapie cellulari a un pubblico globale di professionisti sanitari e investitori.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. La compañía, que se centra en el desarrollo de inmunoterapias celulares derivadas de iPSC para el cáncer y enfermedades autoinmunes, presentará el jueves 19 de septiembre de 2024, a las 12:45 PM ET en Nueva York.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'Eventos y Presentaciones' del sitio web de Fate Therapeutics. La versión archivada estará disponible poco después de que concluya el evento. Esta aparición en la conferencia brinda a Fate Therapeutics la oportunidad de mostrar su innovadora cartera y su progreso en el campo de las inmunoterapias celulares a una audiencia global de profesionales de la salud e inversores.
Fate Therapeutics (NASDAQ: FATE), 임상 단계의 생명공학 회사가 2024 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 암 및 자가면역 질환을 위한 iPSC 유래 세포 면역요법 개발에 중점을 둔 이 회사는 2024년 9월 19일 목요일, 오후 12:45 ET에 뉴욕에서 발표할 예정입니다.
투자자 및 관심 있는 당사자는 Fate Therapeutics 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 이벤트 종료 직후 아카이브 버전을 이용할 수 있습니다. 이번 회의 참여는 Fate Therapeutics가 건강 관리 전문가 및 투자자로 구성된 글로벌 청중에게 세포 면역 요법 분야의 혁신적인 파이프라인과 진행 상황을 보여줄 수 있는 기회를 제공합니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. L'entreprise, qui se concentre sur le développement de thérapies immunologiques cellulaires dérivées d'iPSC pour le cancer et les maladies auto-immunes, présentera le jeudi 19 septembre 2024, à 12h45 ET à New York.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section 'Événements & Présentations' du site Web de Fate Therapeutics. La version archivée sera disponible peu après la fin de l'événement. Cette participation à la conférence offre à Fate Therapeutics l'occasion de présenter son portefeuille innovant et ses avancées dans le domaine des thérapies immunologiques cellulaires à un public mondial de professionnels de la santé et d'investisseurs.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Das Unternehmen, das sich auf die Entwicklung von aus iPSC abgeleiteten zellulären Immuntherapien für Krebs und Autoimmunerkrankungen konzentriert, wird am Donnerstag, den 19. September 2024, um 12:45 PM ET in New York präsentieren.
Investoren und Interessierte können über den Bereich 'Veranstaltungen & Präsentationen' auf der Website von Fate Therapeutics auf einen Live-Stream der Präsentation zugreifen. Die archivierte Version wird kurz nach Abschluss der Veranstaltung verfügbar sein. Diese Konferenzteilnahme bietet Fate Therapeutics die Gelegenheit, sein innovatives Portfolio und den Fortschritt im Bereich der zellulären Immuntherapien einem globalen Publikum von Fachleuten im Gesundheitswesen und Investoren vorzustellen.
- None.
- None.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York.
A live webcast, if recorded, of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
When is Fate Therapeutics (FATE) presenting at the 2024 Cantor Global Healthcare Conference?
How can investors access Fate Therapeutics' (FATE) presentation at the 2024 Cantor Global Healthcare Conference?
What type of therapies is Fate Therapeutics (FATE) developing?
Will the webcast of Fate Therapeutics' (FATE) presentation be available after the event?
